| Year | Title | Author(s) |
| 2025 |
Ribosome Biogenesis and Function in Cancer: From Mechanisms to Therapy
Cancers |
Gitareja, K Chelliah, SS Sanij, E Sandhu, S Kang, J Khot, A |
| 2025 |
Intraindividual epigenetic heterogeneity underlying phenotypic subtypes of advanced prostate cancer
Nature Communications |
Mizuno, K Ku, SY Venkadakrishnan, VB Bakht, MK Sigouros, M Chan, JN Trigos, A Driskill, JH Manohar, J King, A Presser, AG Kim, MJ Tewari, AK Long, HW Quigley, D Choueiri, TK Balk, S Hill, S Mosquera, JM Einstein, D Sandhu, S Taplin, ME Beltran, H |
| 2023 |
Increased Thyroidal Activity on Routine FDG-PET/CT after Combination Immune Checkpoint Inhibition: Temporal Associations with Clinical and Biochemical Thyroiditis
Cancers |
Galligan, A Wallace, R Krishnamurthy, B Kay, TWH Sachithanandan, N Chiang, CR Sandhu, S Hicks, RJ Iravani, A |
| 2023 |
Imaging for assessment of cancer treatment response to immune checkpoint inhibitors can be complementary in identifying hypophysitis
Frontiers In Endocrinology |
Galligan, A Iravani, A Lasocki, A Wallace, R Weppler, AM Sachithanandan, N Chiang, CR Colman, PG Wentworth, J Spain, L Au-Yeung, G Lee, BLD Kay, TWH Hicks, RJ Sandhu, S Krishnamurthy, B |
| 2022 |
Reaction hijacking of tyrosine tRNA synthetase as a new whole-of-life-cycle antimalarial strategy
Cancers |
Inderjeeth, AJ Topp, M Sanij, E Castro, E Sandhu, S |
| 2021 |
CX-5461 Sensitizes DNA Damage Repair-proficient Castrate-resistant Prostate Cancer to PARP Inhibition
Molecular Cancer Therapeutics |
Lawrence, MG Porter, LH Choo, N Pook, D Grummet, JP Pezaro, CJ Sandhu, S Ramm, S Luu, J Bakshi, A Goode, DL Sanij, E Pearson, RB Hannan, RD Simpson, KJ Taylor, RA Risbridger, GP Furic, L |
| 2018 |
Diabetes associated with immune checkpoint inhibition: presentation and management challenges
Diabetic Med. |
Galligan, A Xu, W Fourlanos, S Nankervis, A Chiang, C Mant, AM Parente, P Rischin, D Krishnamurthy, B Sandhu, S Colman, PG |